1. Survival With Cemiplimab in Recurrent Cervical Cancer
- Author
-
Krishnansu S, Tewari, Bradley J, Monk, Ignace, Vergote, Austin, Miller, Andreia C, de Melo, Hee-Seung, Kim, Yong Man, Kim, Alla, Lisyanskaya, Vanessa, Samouëlian, Domenica, Lorusso, Fernanda, Damian, Chih-Long, Chang, Evgeniy A, Gotovkin, Shunji, Takahashi, Daniella, Ramone, Joanna, Pikiel, Beata, Maćkowiak-Matejczyk, Eva M, Guerra Alía, Nicoletta, Colombo, Yulia, Makarova, Danny, Rischin, Stephanie, Lheureux, Kosei, Hasegawa, Keiichi, Fujiwara, Jingjin, Li, Shaheda, Jamil, Vladimir, Jankovic, Chieh-I, Chen, Frank, Seebach, David M, Weinreich, George D, Yancopoulos, Israel, Lowy, Melissa, Mathias, Matthew G, Fury, Ana, Oaknin, Rachna T, Shroff, Tewari, K, Monk, B, Vergote, I, Miller, A, de Melo, A, Kim, H, Kim, Y, Lisyanskaya, A, Samouëlian, V, Lorusso, D, Damian, F, Chang, C, Gotovkin, E, Takahashi, S, Ramone, D, Pikiel, J, Maćkowiak-Matejczyk, B, Guerra Alía, E, Colombo, N, Makarova, Y, Rischin, D, Lheureux, S, Hasegawa, K, Fujiwara, K, Li, J, Jamil, S, Jankovic, V, Chen, C, Seebach, F, Weinreich, D, Yancopoulos, G, Lowy, I, Mathias, M, Fury, M, and Oaknin, A
- Subjects
Adult ,Aged, 80 and over ,cervical cancer ,Programmed Cell Death 1 Receptor ,Uterine Cervical Neoplasms ,Obstetrics and Gynecology ,General Medicine ,Adenocarcinoma ,Middle Aged ,Antibodies, Monoclonal, Humanized ,Survival Analysis ,Carcinoma, Adenosquamous ,Antineoplastic Agents, Immunological ,Biomarkers, Tumor ,Disease Progression ,Quality of Life ,Humans ,Female ,Neoplasm Recurrence, Local ,Aged - Abstract
Background: Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)-blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in this population. Methods: In this phase 3 trial, we enrolled patients who had disease progression after first-line platinum-containing chemotherapy, regardless of their programmed cell death ligand 1 (PD-L1) status. Women were randomly assigned (1:1) to receive cemiplimab (350 mg every 3 weeks) or the investigator's choice of single-agent chemotherapy. The primary end point was overall survival. Progression-free survival and safety were also assessed. Results: A total of 608 women were enrolled (304 in each group). In the overall trial population, median overall survival was longer in the cemiplimab group than in the chemotherapy group (12.0 months vs. 8.5 months; hazard ratio for death, 0.69; 95% confidence interval [CI], 0.56 to 0.84; two-sided P
- Published
- 2022
- Full Text
- View/download PDF